High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations
Open Access
- 1 March 2007
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 21 (6) , 1318-1321
- https://doi.org/10.1038/sj.leu.2404635
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Loss of Response to Imatinib: Mechanisms and ManagementHematology-American Society Hematology Education Program, 2005
- Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to ImatinibClinical Chemistry, 2004
- Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999